Sinolink Securities Co., Ltd. has released a research report stating that savolitinib is approaching an important milestone inflection point where strong data will be converted into commercial sales growth.
In the near term, the firm remains bullish on the two major studies of savolitinib set to be presented at ESMO as catalysts; in the medium to long term, the firm is equally optimistic that the drug will see simultaneous commercialization growth inflection points in both domestic and overseas markets.
Based on the above analysis, a "Buy" rating is assigned to HUTCHMED, the rights holder of savolitinib.
The main points of the Sinolink Securities report are as follows:
The MET-targeted drug space is accelerating its iteration, with savolitinib leading the positioning. MET gene abnormalities include MET-ex14 skipping mutations, MET activating mutations, MET gene amplification, MET gene fusions, and MET protein overexpression, among which MET gene amplification and MET protein overexpression have relatively large patient bases.
The gold standard for detecting MET gene amplification among MET gene abnormalities is FISH, while MET protein overexpression relies on IHC immunohistochemistry testing.
Historical studies show that the proportion of MET gene amplification positivity after EGFR-TKI progression (FISH detection, GCN≥5 and/or MET/CEP7≥2) is approximately one-third, and the willingness of these patients to undergo re-biopsy is approximately 40%-50%; c-MET protein overexpression is one of the factors inducing cancer, with high expression accounting for approximately one-third of NSCLC cases.
Corresponding MET-targeted drugs are divided into three categories: small molecule MET-TKIs (such as HUTCHMED/AZ's savolitinib), anti-MET antibodies/bispecific antibodies (such as J&J's amivantamab), and c-MET ADCs (such as AbbVie's ABBV-400), with small molecule MET-TKIs being the current mainstream clinical treatment.
2L EGFRmt/METamp sees a key breakthrough, with savolitinib presenting global clinical results at ESMO at the highest specification. EGFR mutations are one of the largest mutation factors among NSCLC patients; in 2025 alone, global sales of osimertinib (EGFR-TKI) reached US$7.254 billion, of which an estimated three-quarters came from the 1L market. The market after EGFR-TKI resistance is enormous, with MET gene abnormalities accounting for a large proportion.
The firm estimates that the neutral forecast market size for 2L treatment of EGFRmt MET-amplified NSCLC is approximately US$700 million.
The 2L EGFRmt/METamp NSCLC treatment landscape was previously relatively blank, but the treatment paradigm is becoming increasingly clear: both CSCO (China's authoritative guidelines) and NCCN (US authoritative guidelines) are placing greater emphasis on MET amplification testing, with CSCO having upgraded MET amplification testing from a Class II recommendation to Class I in 2026, accompanied by the emergence and popularization of MET-targeted drugs — savolitinib, as the only drug to achieve Phase III clinical success in this indication, will be launched in China and globally, and is expected to maintain a relatively long commercialization exclusivity period.
Around 2L EGFRmt/MET-amplified NSCLC, HUTCHMED/AZ have laid out three studies: SACHI — a China Phase III study (results published, ITT mPFS=8.2mo vs. 4.5mo, HR=0.34; mOS=22.9mo vs. 17.7mo, HR=0.84); SAVANNAH — a global Phase II clinical trial (results published, ITT mPFS=7.4mo, Asian mPFS=7.6mo); SAFFRON — a global Phase III study (mPFS=7.6mo vs. 5.4mo, HR=0.55; mOS=17.8mo vs. 12.9mo, HR=0.68). Savolitinib demonstrates prominent efficacy in this patient population.
1L EGFRmt/MET-overexpressing NSCLC has significant unmet clinical needs, and savolitinib will maintain exclusivity for a considerable period. Currently, relevant guidelines have no clear and independent diagnostic and treatment pathway for EGFRmt/MET-overexpressing NSCLC, so this market has enormous unmet needs.
Savolitinib is expected to become the first drug launched in this market — its registrational Phase III clinical results were published on October 26, 2026 in LBA format (mPFS=24.8mo vs. 11.1mo, HR=0.45; mOS=44.5mo vs. 34.9mo, HR=0.48), after which HUTCHMED plans to submit a new indication marketing application for savolitinib for first-line treatment in China by the end of 2026.
Breaking through the ceiling of a single indication, the second growth curve drives explosive growth for savolitinib both domestically and internationally. Savolitinib not only has data catalysts at ESMO — both datasets were released in the high-specification LBA format — but more importantly, savolitinib is also approaching an important milestone inflection point where strong data will be converted into commercial sales growth.
Looking back at history, savolitinib had been trapped in the red ocean market of MET-ex14 skipping mutation NSCLC, with lackluster sales; however, starting from 2027, the drug is expected to see explosive growth: ① Domestically, for 2L EGFRmt/METamp NSCLC, AZ will push for medical insurance negotiations in 2026; for 1L EGFRmt/MET-overexpressing NSCLC, the Phase III registrational study SANOVO final results will be published on October 26, 2026, after which HUTCHMED and AZ are expected to push for NDA submission for this indication as soon as possible. ② Overseas, AZ has already submitted an NDA to the FDA on September 29, 2026 for the 2L EGFRmt/METamp NSCLC indication. ③ The new indications all adopt the combination with osimertinib regimen, which will improve the sales ecosystem of AZ's blockbuster osimertinib and extend its lifecycle, thereby greatly motivating AZ's enthusiasm to promote the commercial sales of savolitinib.
Risk warnings: MET gene abnormality detection rate falling short of expectations, deteriorating competitive landscape risk, clinical data falling short of expectations, medical insurance negotiations falling short of expectations, and launch progress falling short of expectations.
Comments